Breast-Conserving Therapy for Triple-Negative Breast Cancer

Gangi, Afshin; Chung, Alice; Mirocha, James; Liou, Douglas Z.; Leong, Trista; Giuliano, Armando E.

doi:10.1001/jamasurg.2013.3037

Cited by 67 publications

(47 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Haffty et al 33 as well as Freedman et al 34 also found no significant differences in IBTR among patients treated with BCT when comparing TNBC with non-TNBC. A recent study by Gangi et al 35 examined outcome among 1,851 consecutive patients treated between 2000 and 2012, during which trastuzumab was routinely used for HER2-positive patients. There was no significant difference in IBTR among patients with TNBC compared with other subtypes of tumors.…”

Section: Median Year Of Recruitmentmentioning

confidence: 99%

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

Purpose. Controversy exists regarding the optimal margin width in breast-conserving surgery for invasive breast cancer. Methods. A multidisciplinary consensus panel used a meta-analysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 33 studies including 28,162 patients as the primary evidence base for consensus. Results. Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with a two-fold increase in the risk of IBTR compared with negative margins. This increased risk is not mitigated by favorable biology, endocrine therapy, or a radiation boost. More widely clear margins than no ink on tumor do not significantly decrease the rate of IBTR compared with no ink on tumor. There is no evidence that more widely clear margins reduce IBTR for young patients or for those with unfavorable biology, lobular cancers, or cancers with an extensive intraductal component. Conclusion. The use of no ink on tumor as the standard for an adequate margin in invasive cancer in the era of multidisciplinary therapy is associated with low rates of IBTR and has the potential to decrease re-excision rates, improve cosmetic outcomes, and decrease health care costs.

show abstract

Section: Median Year Of Recruitmentmentioning

confidence: 99%

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…In total, 1,182 titles were reviewed, 5 studies [14,15,18,19,20] including 2,922 non-TNBC and 510 TNBC cases were selected. The characteristics of included studies are summarized in supplemental table 1 A-C (www.karger.com/?DOI=441436) .…”

Section: Resultsmentioning

confidence: 99%

“…The remaining 3 studies did not define clear cutoffs for positivity of ER and PR. HER2 status was obtained through IHC in 2 studies [14,18], and IHC/fluorescent in situ hybridization (FISH) in 3 studies [15,19,20]. During the study period of Solin et al [14], the currently accepted system of scoring HER2 expression as 0, 1+, 2+, or 3+ was not generally used.…”

Section: Resultsmentioning

confidence: 99%

“…TNBC is associated with an increased risk of recurrence within the first 3 years and increased mortality during the first 3-5 years after diagnosis because of aggressive clinicopathological features and ineffectiveness of endocrine therapy or trastuzumab [7,8,9,10]. Some studies demonstrated that TNBC was worse than non-TNBC in its response to treatment with BCS followed by RT [11,12,13,14,15], while others showed no such difference [16,17,18,19,20]. Identifying the effectiveness of BCS plus RT (especially local control rate) in the treatment of TNBC would allow clinicians to offer better local treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis

Pan

Jiang

et al. 2015

Breast Care

View full text Add to dashboard Cite

Background: The aim of this study was to compare the efficacy of breast conservation surgery (BCS) followed by radiotherapy (RT) in triple negative breast cancer (TNBC) versus non-TNBC. Methods: We searched the MEDLINE and EMBASE databases from inception through March 31, 2014, using search terms related to TNBC, BCS, and RT. Studies comparing the efficacy of BCS followed by RT in TNBC versus non-TNBC were reviewed. Results: 5 studies including 2,922 non-TNBC and 510 TNBC cases were selected. The overall quality of included studies was deemed moderate to high. Compared with non-TNBC, the pooled relative risk of 5-year local relapse-free survival was 1.315 (95% confidence interval (CI) 0.967-1.789; p = 0.008) for TNBC, and that of 5-year overall survival, regional relapse-free survival, and distant metastasis-free survival was 1.929 (95% CI 1.392-2.674; p = 0.000), 3.052 (95% CI 1.629-5.715; p = 0.000), and 2.407 (95% CI 1.910-3.034; p = 0.000), respectively. Conclusion: The local control rate of TNBC treated with BCS plus RT is similar to that of non-TNBC.

show abstract

“…Therefore, patients with TNBCs do not benefit from commonly used antiestrogen and herceptin-based therapies (4,5). Although chemotherapy is currently the mainstay of systemic treatment for breast cancer, patients with TNBC disease have a worse outcome after chemotherapy than patients with other subtypes of breast cancer (6,7). Previous studies revealed that neoadjuvant treatment involving the administration of chemotherapy before surgery was effective in a minority of women with TNBCs who showed a complete pathologic response and an excellent outcome; however, a relatively poor outcome was observed for the majority of the population with residual disease after treatment.…”

Section: Introductionmentioning

confidence: 99%

Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells

Liu

Wang

et al. 2015

Oncology Reports

View full text Add to dashboard Cite

Abstract. Triple-negative breast cancer (TNBC), characterized by distinct biological and clinicopathological features, has a poor prognosis due to lack of effective therapeutic targets. Our previous data revealed that high levels of USP39 were selectively present in TNBC samples compared with their normal breast tissue samples and USP39 was also expressed at different levels in cultured TNBC cells and normal breast cells. Yet, the underlying cellular and molecular mechanisms of USP39 remain unclear. In the present study, we describe a doxycycline (DOX)-regulated lentiviral vector system expressing shRNA or cDNA of the USP39 gene in the TNBC cell line MDA-MB-231. USP39 expression was knocked down by the miR-30-based inducible lentiviral short hairpin RNA (shRNA) delivery system or overexpressed by the inducible cDNA system. The inducible shRNA-mediated downregulation of USP39 expression markedly reduced the proliferation and colony-forming ability of MDA-MB-231 cells, while overexpression of USP39 by the inducible system did not promote cancer cell proliferation. The lentiviral vector-mediated Tet-on system demonstrated efficient and inducible knockdown of USP39 or overexpression of USP39 in TNBC cells, facilitating a wide variety of applications for gene knockdown and overexpression experiments in gene functional studies in vitro and in vivo.

show abstract

Breast-Conserving Therapy for Triple-Negative Breast Cancer

Abstract: Breast-conserving therapy for TNBC is not associated with increased LR compared with non-TNBC subtypes. However, the TNBC phenotype correlates with worse overall survival. Breast-conserving therapy is appropriate for patients with TNBC.

Cited by 67 publications

References 26 publications

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis

Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells

Contact Info

Product

Resources

About